12 Jan Measuring What Matters to Patients
This research study is being conducted to learn more about what is important to those diagnosed with a myelodysplastic disease in efforts to improve how drug developers measure quality of life and the patient experience when developing new products. The objective of this research study will be to explore your personal values, goals, needs, and symptomatic experiences in the treatment of patients’ conditions, specifically in regards to quality of life; in efforts to align existing quality of life measurement instruments to capture change. To learn more visit http://www.MDSqualityofLifeStudy.com.
Participant Eligibility
+ Age 18 years and older
+ Acute Myelogenous Leukemia (AML) patients (newly diagnosed, or up to 1 year of anti-leukemic treatment)
OR
+ High-Risk Myelodysplastic (MDS) patients (defined using the IPSS score of intermediate-2 and High groups)
+ Currently under the care of a licensed Oncologist/Hematologist for the treatment of your disease
+ Have access to a computer or Mobile Device to participate in remote virtual video interviews and complete web-based survey
Contact
Anthony J. Messina
(772) 528-9643
Additional Study Details
Full Study Title
Measuring What Matters to Patients: A Multiple Methods Sequential Study of Disease Burden, Quality of Life, and the Alignment of Patient-Reported Outcome Measurements for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients
Investigator(s)
Principal Investigator: Mary A. Corcoran, PhD
Co-Investigator: Anthony J. Messina, Ph.D. (c).
Accepts Healthy Volunteers?
No
Study Site(s)
Remote / Virtual
N/A
St. Lucie, Florida 34952
